CDAK insider filings
Codiak BioSciences, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-03-30. Screen CDAK transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for CDAK between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Codiak BioSciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-03-30 | 4 | Howze Yalonda — See Remarks | Sale (S): 1,628 @ $0.20 | EDGAR |
| 2023-03-30 | 4 | Sathyanarayanan Sriram — Chief Scientific Officer | Sale (S): 11,762 @ $0.17 | EDGAR |
| 2023-03-30 | 4 | Konstantinov Konstantin — Chief Technology Officer | Sale (S): 7,432 @ $0.20 · Sale (S): 1,932 @ $0.20 | EDGAR |
| 2023-03-30 | 4 | Barna Nicole — See Remarks | Sale (S): 5,373 @ $0.17 · Sale (S): 1,932 @ $0.17 | EDGAR |
| 2023-03-30 | 4 | Bain Linda — Chief Financial Officer | Sale (S): 13,412 @ $0.17 | EDGAR |
| 2023-03-30 | 4 | WILLIAMS DOUGLAS E — President & CEO, Director | Sale (S): 41,667 @ $0.18 | EDGAR |
| 2023-02-21 | 4 | Konstantinov Konstantin — Chief Technology Officer | Option exercise (M): 4,200 · Sale (S): 1,308 @ $2.21 · Option exercise (M): 4,200 · Sale (S): 1,391 @ $0.59 · Option exercise (M): 4,200 (derivative) @ $0 · Option exercise (M): 4,200 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | Sathyanarayanan Sriram — Chief Scientific Officer | Option exercise (M): 7,350 · Sale (S): 2,283 @ $2.21 · Option exercise (M): 7,350 · Sale (S): 2,407 @ $0.59 · Option exercise (M): 7,350 (derivative) @ $0 · Option exercise (M): 7,350 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | Haddock Jason — Director | Option exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | Barna Nicole — See Remarks | Option exercise (M): 3,150 · Sale (S): 984 @ $2.21 · Option exercise (M): 3,150 · Sale (S): 1,274 @ $0.59 · Option exercise (M): 3,150 (derivative) @ $0 · Option exercise (M): 3,150 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | Howze Yalonda — See Remarks | Option exercise (M): 4,857 · Sale (S): 1,512 @ $2.21 · Option exercise (M): 4,856 · Sale (S): 1,603 @ $0.59 · Option exercise (M): 4,857 (derivative) @ $0 · Option exercise (M): 4,856 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | Bernstein Karen — Director | Option exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | Bain Linda — Chief Financial Officer | Option exercise (M): 7,613 · Sale (S): 2,364 @ $2.21 · Option exercise (M): 7,613 · Sale (S): 2,570 @ $0.59 · Option exercise (M): 7,613 (derivative) @ $0 · Option exercise (M): 7,613 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | GILLIS STEVEN — Director | Option exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | MELAS KYRIAZI THEO — Director | Option exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | WILLIAMS DOUGLAS E — President & CEO, Director | Option exercise (M): 22,969 · Sale (S): 7,112 @ $2.21 · Option exercise (M): 22,969 · Sale (S): 7,681 @ $0.59 · Option exercise (M): 22,969 (derivative) @ $0 · Option exercise (M): 22,969 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | COONEY CHARLES L — Director | Option exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Sathyanarayanan Sriram — Chief Scientific Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Konstantinov Konstantin — Chief Technology Officer | Grant/award (A): 145,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Howze Yalonda — See Remarks | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Barna Nicole — See Remarks | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Mauro David J — Chief Medical Officer | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Bain Linda — Chief Financial Officer | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | WILLIAMS DOUGLAS E — President & CEO, Director | Grant/award (A): 465,000 (derivative) @ $0 | EDGAR |
| 2023-01-23 | 4 | Konstantinov Konstantin — Chief Technology Officer | Option exercise (M): 2,800 · Sale (S): 1,069 @ $0.58 · Option exercise (M): 2,800 (derivative) @ $0 | EDGAR |
| 2023-01-23 | 4 | Sathyanarayanan Sriram — Chief Scientific Officer | Option exercise (M): 2,834 · Sale (S): 1,082 @ $0.58 · Option exercise (M): 2,834 (derivative) @ $0 | EDGAR |
| 2023-01-23 | 4 | Howze Yalonda — See Remarks | Option exercise (M): 4,000 · Sale (S): 1,512 @ $0.58 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2023-01-23 | 4 | Barna Nicole — See Remarks | Option exercise (M): 2,167 · Sale (S): 836 @ $0.57 · Option exercise (M): 2,167 (derivative) @ $0 | EDGAR |
| 2023-01-23 | 4 | Bain Linda — Chief Financial Officer | Option exercise (M): 5,000 · Sale (S): 1,880 @ $0.57 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2023-01-23 | 4 | WILLIAMS DOUGLAS E — See Remarks, Director | Option exercise (M): 13,667 · Sale (S): 5,075 @ $0.57 · Option exercise (M): 13,667 (derivative) @ $0 | EDGAR |
| 2022-09-20 | 4 | Sathyanarayanan Sriram — Chief Scientific Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2022-09-20 | 4 | Konstantinov Konstantin — Chief Technology Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2022-09-20 | 4 | Barna Nicole — See Remarks | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2022-09-20 | 4 | Howze Yalonda — See Remarks | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2022-09-20 | 4 | Mauro David J — Chief Medical Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2022-09-20 | 4 | Bain Linda — Chief Financial Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2022-09-16 | 4 | Flagship Ventures Fund V General Partner LLC — 10% owner Flagship Ventures Fund V, L.P. — 10% owner Flagship V VentureLabs Rx Fund, L.P. — 10% owner AFEYAN NOUBAR — 10% owner | Purchase (P): 722,590 · Purchase (P): 210,743 · Purchase (P): 722,590 (derivative) · Purchase (P): 210,743 (derivative) | EDGAR |
| 2022-09-15 | 4 | GILLIS STEVEN — Director | Purchase (P): 5,000,000 · Purchase (P): 5,000,000 (derivative) | EDGAR |
| 2022-09-15 | 4 | ARCH Venture Fund VIII, L.P. — 10% owner ARCH Venture Fund VIII Overage, L.P. — 10% owner CRANDELL KEITH — 10% owner BYBEE CLINTON — 10% owner NELSEN ROBERT — 10% owner ARCH Venture Partners VIII, LLC — 10% owner ARCH Venture Partners VIII, L.P. — 10% owner | Purchase (P): 5,000,000 @ $1.50 · Purchase (P): 5,000,000 (derivative) | EDGAR |
| 2022-06-21 | 4 | Haddock Jason — Director | Grant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | Eggimann Anne-Virginie — Director | Grant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | Pandite Arundathy N. — Director | Grant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | Bernstein Karen — Director | Grant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | GILLIS STEVEN — Director | Grant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | MELAS KYRIAZI THEO — Director | Grant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | COONEY CHARLES L — Director | Grant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-05-04 | 4 | Mauro David J — Chief Medical Officer | Grant/award (A): 200,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-02-18 | 4 | MELAS KYRIAZI THEO — Director | Grant/award (A): 8,750 (derivative) @ $0 | EDGAR |
| 2022-02-18 | 4 | WILLIAMS DOUGLAS E — President & CEO, Director | Grant/award (A): 61,250 (derivative) @ $0 · Grant/award (A): 91,875 (derivative) @ $0 | EDGAR |
| 2022-02-18 | 4 | COONEY CHARLES L — Director | Grant/award (A): 8,750 (derivative) @ $0 | EDGAR |
Recent 8-K events — Codiak BioSciences, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-03-29 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-03-27 | 8-K | 1.03 — Bankruptcy or Receivership ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-09-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-08-30 | 8-K | ? 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-06-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-06-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-06-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2022-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CDAK returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs